[en] Respiratory syncytial virus (RSV) is a serious pathogen causing significant morbidity, especially in premature infants and infants with chronic lung disease or significant congenital heart disease. There is no specific treatment for RSV infection and the therapy is essentially supportive. Therefore, prophylaxis is the best strategy against RSV disease. Passive immunization with monoclonal antibodies (palivizumab) provides protection against severe RSV infection and significantly reduces hospitalizations in high-risk childrens. However, palizumab is an expensive drug and its use should be reserved for children at the highest risk of severe RSV disease.
Disciplines :
Pediatrics
Author, co-author :
De Halleux, Virginie ; Centre Hospitalier Universitaire de Liège - CHU > Néonatologie
Lombet, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Rigo, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie - Néonatologie
Language :
French
Title :
Prevention de l'infection respiratoire a VRS par immunoglobulines monoclonales specifiques (palivizumab, Synagis)
Alternative titles :
[en] Respiratory Syncytial Immunoprophylaxis with Palivizumab
Publication date :
2007
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Simoes E. - Palivizumab long-term outcomes study : primary and secondary analyses. In : 4th Global Experts' Meeting on Respiratory Viruses; 2006 19-18 septembre 2006; Monaco; 2006. p. 10-11.
Korppi M, Piippo-Savolainen E, Korhonen K, et al. - Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol, 2004, 38, 155-160.
Sigurs N, Gustafsson PM, Bjarnason R, et al. - Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med, 2005, 171, 137-141.
Stein RT, Sherrill D, Morgan WJ, et al. - Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet, 1999, 354, 541-545.
Harkensee C, Brodlie M, Embleton ND, et al. - Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect, 2006, 52, 2-8.
Mejias A, Cavez-Bueno S, Sanchez P. - Respiratory syncytial virus prophylaxis. Neoreviews, 2005, 6, 26-31.
Venkatesh MP, Weisman LE. - Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Rev Vaccines, 2006, 5, 261-268.
The IMpact study. - Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 1998, 102, 531-537.
Parnes C, Guillermin J, Habersang R, et al. - Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol, 2003, 35, 484-489.
Feltes TF, Cabalka AK, Meissner HC, et al. - Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr, 2003, 143, 532-540.
Embleton ND, Harkensee C, McKean MC. - Palivizumab for preterm infants. Is it worth it ? Arch Dis Child Fetal Neonatal Ed, 2005, 90, F286-289.
